May 16, 2008
Landmark ATHENA Study Findings With Multaq (dronedarone) Shows 24%...
“As a consequence, dronedarone is the first potential treatment for atrial fibrillation, which was demonstrated in the ATHENA trial to reduce cardiovascular hospitalization or mortality in patients with AF”
Sanofi-aventis announced today that findings from the landmark ATHENA study showed Multaq , a potential therapy for the treatment of patients with atrial fibrillation or atrial flutter, decreased the risk of ... via Med Ad News
Read full story from Med Ad News
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.
| Topic | Updated | Last By | Comments |
|---|---|---|---|
| Claims administrator: Interim payments in $4.85... | 4 hr | Jerimiah | 1048 |
| Vioxx claimants rush to join $4.85B settlement ... (from Jan '08) | 4 hr | Jerimiah | 684 |
| MPI Research cutting jobs in Mattawan | 5 hr | Former MPI E... | 18 |
| Cymbalta leads the way for Lilly (from Feb '07) | 6 hr | Stranger In ... | 234 |
| Merck to fund Vioxx settlement in August | 8 hr | Peggy | 1375 |
| Northwestern Memorial Hospital patient's compla... | 9 hr | Old RN | 2 |
| Johnson & Johnson buying Mentor for $1.07B | 10 hr | Anon Amous | 3 |
Taurus
Most Popular